文献速递肝病消化道肿瘤与早癌

17β-羟基类固醇脱氢酶13基因变异对酒精性肝病患者肝细胞癌发生的保护作用

A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
PubMed 文献 · Hepatology · 2019-04-25

研究纳入来自四个中心的3315例欧洲肝细胞癌或慢性肝病患者,分析HSD17B13 rs72613567变异与肝细胞癌的关系。结果显示该功能缺失变异在酒精性肝病、非酒精性脂肪性肝病和丙型肝炎患者中均与肝细胞癌风险降低相关,尤其在酒精性肝病患者中保护作用显著。

要点

  • HSD17B13 rs72613567 TA等位基因在肝细胞癌患者中频率显著降低。
  • 在酒精性肝病患者中,TA等位基因携带者发生肝细胞癌的比值比为0.64。
  • 该变异对非酒精性脂肪性肝病和丙型肝炎患者的肝细胞癌也有保护作用。

核心结论

  • HSD17B13 rs72613567功能缺失变异对酒精性肝病患者的肝细胞癌发生具有保护作用。

研究设计与样本

  • 研究纳入来自四个中心的3315例欧洲患者,包括1109例肝细胞癌患者和2206例无肝细胞癌的慢性肝病患者,并纳入33337名健康欧洲个体作为对照。
  • 探索队列285例肝细胞癌患者接受全外显子组测序,验证队列824例肝细胞癌患者及所有慢性肝病患者接受HSD17B13 rs72613567基因分型。
  • 采用卡方检验和逻辑回归比较基因型分布。

主要发现

  • 在探索队列中,肝细胞癌患者HSD17B13 rs72613567的TA等位基因频率较健康对照显著降低(P=1.52×10⁻⁶)。
  • 在验证队列中,无肝细胞癌的慢性肝病患者TA等位基因携带者频率为39%,低于健康个体的47%(P<0.0001)。
  • TA等位基因对酒精性肝病患者具有保护作用(OR=0.73;95%CI 0.65-0.82;P<0.0001)。
  • TA等位基因对非酒精性脂肪性肝病患者具有保护作用(OR=0.64;95%CI 0.49-0.83;P=0.0007)。
  • TA等位基因对丙型肝炎患者具有保护作用(OR=0.71;95%CI 0.60-0.85;P=0.0002)。

关键数值与推荐

  • 在酒精性肝病患者中,合并肝细胞癌的TA等位基因携带者比例为32%,低于无肝细胞癌的慢性肝病患者的40%,校正年龄、性别和纤维化后OR=0.64(95%CI 0.46-0.87;P=0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recently, a loss of function variant (rs72613567) in 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) has been identified as protective of nonalcoholic (NAFLD) and alcoholic liver disease (ALD). However, the role of this single-nucleotide polymorphism (SNP) in the development of hepatocellular carcinoma (HCC) is currently unknown. A total of 3,315 European patients with HCC (n = 1,109) or without HCC, but with chronic liver disease (CLD; n = 2,206), from four centers were analyzed either by whole-exome sequencing (WES; exploratory cohort, 285 HCC) or genotyped for HSD17B13 rs72613567 (validation cohort, 824 HCC and all CLD). We included a control group of 33,337 healthy European individuals from the Exome Aggregation Consortium. We compared distribution of genotype using the chi-square test and logistic regression. In the exploratory cohort analyzed by WES, frequency of the TA allele of HSD17B13 rs72613567 was significantly decreased in HCC patients compared to healthy controls (P = 1.52 × 10-06 ). In the validation cohort, frequency of TA allele carriers was also decreased in patients with CLD and without HCC (39%) compared to healthy individuals (47%; P < 0.0001). The protective effect of the TA allele of HSD17B13 rs72613567 was identified in patients with ALD (odds ratio [OR] = 0.73; 95% confidence interval [CI], 0.65-0.82; P < 0.0001), NAFLD (OR = 0.64; 95% CI, 0.49-0.83; P = 0.0007), and hepatitis C (OR = 0.71; 95% CI, 0.60-0.85; P = 0.0002). In patients with ALD, the proportion of TA allele carriers with HCC was significantly lower (32%) than in CLD patients without HCC (40%), even after adjustment for age, sex, and fibrosis (OR = 0.64; 95% CI, 0.46-0.87; P = 0.005). Conclusion: The HSD17B13 rs72613567 loss of function variant is protective of HCC development in patients with ALD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yang J, Trépo E, Nahon P, et al. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. Hepatology. 2019. PMID: 30908678. doi:10.1002/hep.30623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。